Home » FDA Approves New Diabetes Drug Formulation for AstraZenaca
FDA Approves New Diabetes Drug Formulation for AstraZenaca
The FDA approved a new formulation of AstraZenaca’s type-2 diabetes treatment Bydureon, the company said.
The approval includes administration by a modified once-weekly, single-dose autoinjector device, the company said.
Bydureon is indicated for adults with type-2 diabetes whose blood sugar remains uncontrolled on one or more oral medicines in addition to diet and exercise.
Upcoming Events
-
23Apr
-
25Apr
-
07May
-
14May
-
30May